TY - JOUR T1 - Republished: Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 78 LP - 79 DO - 10.1136/dtb.2021.238930rep VL - 60 IS - 5 AU - Lorenzo R Carnio AU - Mary E Johnson Shaw AU - Jack Schnur AU - Damian Casadesus Y1 - 2022/05/01 UR - http://dtb.bmj.com/content/60/5/78.abstract N2 - Terbinafine is a commonly used antifungal medication. Its side effects, while widely known, are rarely described and can be missed by the medical community. We present a 55-year-old woman who visited her primary care physician with onychomycosis. She started treatment with terbinafine, and 1 week later developed a rash in the left flank that extended to the chest, back, and upper part of lower extremities. Laboratory results showed elevated liver enzymes. A treatment with steroids did not improve the rash and she was admitted to our institution. She was started with intravenous dexamethasone, topical hydrocortisone and triamcinolone. Seven days later the liver enzymes normalised, and the rash resolved on the chest and back. Our patient had concurrent acute generalised exanthematous pustulosis and hepatitis that together has been very rarely associated with terbinafine.In conjunction with BMJ Case Reports, DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions … ER -